Cuorips Inc.

4894 TSE Pharmaceuticals Pharmaceutical
TSE Growth
¥5,260.00
-1.13%
Delayed · cached 15 min
Fair Value Analysis →

Price Chart

Price50-day avg200-day avg

How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.

Strengths

  • Low debt: debt-to-equity of 0.07.
  • Current assets comfortably cover current liabilities (current ratio 15.93).
  • Sales have compounded about 98% a year over five years.

!Watch-points

  • Return on equity is on the lower side at -21.9%.
  • Return on capital employed is on the lower side at -22.3%.
  • The company reported a net loss in the latest period.

These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.

Forensic Checks

Altman Z-ScoreDistress zone
-0.71

In Altman’s study, scores in this range were associated with a higher incidence of financial distress.

Computed without the market-value term.

Piotroski F-ScoreWeak
1 / 4

The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.

Based on 4 of the 9 signals — the rest need data not available for this stock.

These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.

Key Ratios

Market Cap¥434億
Current Price¥ 5,260.00
High / Low¥ 12,400.00 / 3,610.00
Stock P/E-42.24
Book Value¥ 568.01
Dividend Yield0%
ROCE-22.31%
ROE-21.94%
Debt to Equity0.07
Current Ratio15.93
P/B Ratio9.144073
EPS¥ -124.54
PAT Margin-481.62%
Compounded Sales Growth
10 Years
5 Years 97.65%
3 Years
TTM
Compounded Profit Growth
10 Years
5 Years
3 Years
TTM
Stock Price CAGR
10 Years
5 Years
3 Years
1 Year
Return on Equity
10 Years
5 Years
3 Years
Last Year -21.94%
Educational data only. Not a recommendation to buy, sell or hold any security.